ClinicalTrials.gg
TerminatedNCT02032173CONSTELLATIONUpdated Oct 22, 2020Results posted

Efficacy and Safety of Lucentis® Use in Patients With Diabetic Macular Edema Evaluating a Spaced Out Follow-up After Intensive Treatment Phase

A Phase 3 interventional study of Ranibizumab 0.5mg in Macular Edema, Macular Degeneration and Diabetes, sponsored by Novartis Pharmaceuticals. Terminated at 10 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-10-22.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment

Why this study was terminated
Study was prematurely discontinued as it was unethical to continue based on a change in ranibizumab (RFB) marketing authorization.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
31
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 91 studies testing ranibizumab in Macular Edema — none open to participants now, none under way, none of them phase 3. Ranibizumab · Macular Edema.

Enrollment
60th of 91
31 · median 50
Started
2014
with 7 others
Phase 3
25 of 91
none open now
Registered
57th of 91
by date
Lead sponsor
21 of 91
Novartis Pharmaceuticals

Among the 91 studies testing ranibizumab in Macular Edema, this one is the 60th largest by enrollment, is one of 8 that started in 2014, is one of 25 in phase 3, and was the 57th registered.

Macular Edema

758 studies on the registry are indexed under Macular Edema; 65 are open to participants now.

Browse Macular Edema studies →

Open to participants now

None of the 91 studies testing ranibizumab in Macular Edema is open now. The open studies under Macular Edema, anywhere →

About ranibizumab

Ranibizumab: first FDA approval 2006 (LUCENTIS), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 43 Macular Edema studies recruiting now, 31 (72%) set no upper age limit and 7 (16%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 91 studies testing ranibizumab in Macular Edema as a file.
02

Study summary

The study was designed to assess the efficacy and safety of Lucentis® (ranibizumab 0.5 mg) in diabetic patients presenting with reduced visual acuity due to diabetic macular edema and evaluating spacing out of follow-up after initial intensive treatment phase.

Read the detailed description

This was a multicenteric, open-label, phase IIIb study, which comprised of 2 groups: the Main Group and the Rescue Group.

Patient's eligibility was assessed during a screening visit (Visit 1) which took place 14 days maximum before treatment initiation (Visit 2 [Day 0]). All patients were initially included in the Main Group and were to receive an initial loading treatment (6 injections during the intensive treatment phase i.e. every month from Day 0 to Month 5, followed by 2 additional injections at Months 8 and 11). Patients were to be followed-up every 3 months for 18 months (spaced-out follow-up period). Their visual acuity was to be checked at each study visit (Months 3, 6, 8, 11, 14, 17, 20, and 23) to assess their response to treatment. Patients who responded to treatment were maintained in the Main Group. Patients who did not meet pre defined criteria were moved to the Rescue Group and treated at the investigator's discretion.

The trial was terminated before any patient reached month 12.

03

Conditions studied

  • Macular Edema
  • Macular Degeneration
  • Diabetes

Keywords

  • Ranibizumab
  • Diabetic Macular Edema
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Type I or type II diabetes with ≤10%
  • Visual impairment due to a diabetic macular edema
  • Stable antidiabetic treatment (since more than 3 months) or hygiene-dietary

Exclusion criteria

Exclusion Criteria:

  • Inflammation or infection in one eye
  • Women of without an efficient , pregnant or breastfeeding

Other protocol-defined inclusion/exclusion criteria may apply

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
31 participants (actual)

Study arms

  • Experimental
    Ranibizumab 0.5mg

    Intravitreal injection with standard dose of 0.5 mg/0.05mL Pro re nata (PRN)

    Drug: Ranibizumab 0.5mg

Interventions

  • Intravitreal injection with standard dose of 0.5 mg/0.05mL Pro re nata (PRN)

06

What researchers measure

Primary outcomes

  1. Number of Participants With a Stable BCVA in the Study Eye at 24 Months Compared With BCVA at 6 Months

    Best-Corrected Visual Acuity (BCVA) letters were measured using Early Treatment Diabetic Retinopathy Study (EDTRS)-like chart while participants were in a sitting position at a testing distance of 4 meters. The range of EDTRS is 0 to 100 letters. A positive change from baseline of BCVA indicates improvement. Best value on the scale 100, worst 0. The number of participants with a stable BCVA (BCVA score at 6 months minus BCVA score at 24 months ≤4 letters) were reported.

    Time frame: Month 6 and 24

Secondary outcomes

  1. Number of Participants With a Stable BCVA in the Study Eye at 24 Months Compared With BCVA at 11 Months

    Best-Corrected Visual Acuity (BCVA) letters were measured using Early Treatment Diabetic Retinopathy Study (EDTRS)-like chart while participants were in a sitting position at a testing distance of 4 meters. The range of EDTRS is 0 to 100 letters. A positive change from baseline of BCVA indicates improvement. Best value on the scale 100, worst 0. The number of participants with a stable BCVA (BCVA score at 11 months minus BCVA score at 24 months ≤4 letters) was calculated as well as its confidence interval at 95%.

    Time frame: Month 11 and 24

  2. Visual Acuity: Number of Participants Keeping a BCVA Score Gain ≥10 Letters

    Best-Corrected Visual Acuity (BCVA) letters was measured using Early Treatment Diabetic Retinopathy Study (EDTRS)-like chart while participants were in a sitting position at a testing distance of 4 meters. The range of EDTRS is 0 to 100 letters. A positive change from baseline of BCVA indicates improvement. Best value on the scale 100, worst 0. The number of participants maintaining ≥10 letters gains in BCVA (compared to the baseline BCVA \[Day 0\]) value for each visit from Month 3 onwards were reported.

    Time frame: Baseline, Month 3, 6, 8 and 11

  3. Visual Acuity: Number of Participants Keeping a BCVA Score Gain ≥15 Letters

    Best-Corrected Visual Acuity (BCVA) letters was measured using Early Treatment Diabetic Retinopathy Study (EDTRS)-like chart while participants were in a sitting position at a testing distance of 4 meters. The range of EDTRS is 0 to 100 letters. A positive change from baseline of BCVA indicates improvement. Best value on the scale 100, worst 0. The number of participants maintaining ≥15 letters gains in BCVA (compared to the baseline BCVA \[Day 0\]) value for each visit from Month 3 onwards were reported.

    Time frame: Baseline, Months 3, 6, 8 and 11

  4. Visual Acuity: Number of Participants With a BCVA Loss ≥15 Letters at Months 8 and 11 Compared to Month 6 in the Study Eye.

    Best-Corrected Visual Acuity (BCVA) letters were measured using Early Treatment Diabetic Retinopathy Study (EDTRS)-like chart while participants were in a sitting position at a testing distance of 4 meters. The range of EDTRS is 0 to 100 letters. A positive change from baseline of BCVA indicates improvement. Best value on the scale 100, worst 0. Number of participants presenting with a ≥15 letter loss in BCVA (compared to the value observed at 6 months) and leading to a treatment change (Rescue Group) for month 8 and 11 were analyzed.

    Time frame: Months 6, 8 and 11

  5. Visual Acuity : Change of BCVA From Baseline in the Study Eye (ETDRS)

    Best-Corrected Visual Acuity (BCVA) letters was measured using Early Treatment Diabetic Retinopathy Study (EDTRS)-like chart while participants were in a sitting position at a testing distance of 4 meters. The range of EDTRS is 0 to 100 letters. A positive change from baseline of BCVA indicates improvement. Best value on the scale 100, worst 0. The mean variation in BCVA was compared to the baseline BCVA value \[Day 0\] over a period of 24 months for patients in the Main Group.

    Time frame: Baseline, months 1, 2, 3, 4, 5, 6, 8 and 11

  6. Central Retinal Thickness : Change of Log OCT From Baseline in the Study Eye

    Retinal thickness is assessed by optical coherence tomography (OCT) in the study eye. The retina is the light-sensitive part of the eye. OCT is a laser-based, noninvasive, diagnostic system providing high-resolution, three-dimensional images of the retina. A negative mean change from baseline indicates an improvement and a positive mean change from baseline indicates a worsening.The absolute variations of the Central Retinal Thickness (CRT) was measured using a Spectral Domain-Optical Coherence Tomography (SD-OCT) at each visit. Values were calculated as a log OCT (=log\[CRT/200\]).

    Time frame: Baseline, months 1, 2, 3, 4, 5, 6, 8 and 11

  7. Visual Acuity : Change of BCVA From Baseline in the Study Eye (ETDRS) - Rescue Group

    Best-Corrected Visual Acuity (BCVA) letters was measured using Early Treatment Diabetic Retinopathy Study (EDTRS)-like chart while participants were in a sitting position at a testing distance of 4 meters. The range of EDTRS is 0 to 100 letters. A positive change from baseline of BCVA indicates improvement. Best value on the scale 100, worst 0. The mean variation in BCVA was compared to the baseline BCVA value \[Day 0\] over a period of 24 months for patients in the Rescue Group.

    Time frame: Baseline, Months 3, 6, 8 and 11

  8. Central Retinal Thickness : Change of Log OCT From Baseline in the Study Eye - Rescue Group

    Retinal thickness is assessed by optical coherence tomography (OCT) in the study eye. The retina is the light-sensitive part of the eye. OCT is a laser-based, noninvasive, diagnostic system providing high-resolution, three-dimensional images of the retina. A negative mean change from baseline indicates an improvement and a positive mean change from baseline indicates a worsening.The absolute variations of the Central Retinal Thickness (CRT) measured using a Spectral Domain-Optical Coherence Tomography (SD-OCT) at each visit. Values were calculated as a log OCT (=log\[CRT/200\]).

    Time frame: Baseline, Months 3, 6, 8 and 11

  9. Evaluation of the Spaced Out Follow-up on Visual Functions and Quality of Life

    The global score obtained on the Visual Function Questionnaire 25 (VFQ 25) was compared from baseline to months 11 and 24 for the Main group and from baseline to months 12 and 24 for the Rescue group.

    Time frame: baseline, months 11, 12 and 24

07

Results

Posted Oct 22, 2020

Participant flow

Participants were recruited from 10 centers across France.

Participant flow — Overall Study
MilestoneRanibizumab
Started31
Included population - main group31
Rescue group1
Completed0
Not completed31
Withdrew: Discontinuation due to sponsor decision31

Outcome measures

PrimaryNumber of Participants With a Stable BCVA in the Study Eye at 24 Months Compared With BCVA at 6 Months

Best-Corrected Visual Acuity (BCVA) letters were measured using Early Treatment Diabetic Retinopathy Study (EDTRS)-like chart while participants were in a sitting position at a testing distance of 4 meters. The range of EDTRS is 0 to 100 letters. A positive change from baseline of BCVA indicates improvement. Best value on the scale 100, worst 0. The number of participants with a stable BCVA (BCVA score at 6 months minus BCVA score at 24 months ≤4 letters) were reported.

Time frame:
Month 6 and 24

No measurements were reported for this outcome.

SecondaryNumber of Participants With a Stable BCVA in the Study Eye at 24 Months Compared With BCVA at 11 Months

Best-Corrected Visual Acuity (BCVA) letters were measured using Early Treatment Diabetic Retinopathy Study (EDTRS)-like chart while participants were in a sitting position at a testing distance of 4 meters. The range of EDTRS is 0 to 100 letters. A positive change from baseline of BCVA indicates improvement. Best value on the scale 100, worst 0. The number of participants with a stable BCVA (BCVA score at 11 months minus BCVA score at 24 months ≤4 letters) was calculated as well as its confidence interval at 95%.

Time frame:
Month 11 and 24

No measurements were reported for this outcome.

SecondaryVisual Acuity: Number of Participants Keeping a BCVA Score Gain ≥10 Letters

Best-Corrected Visual Acuity (BCVA) letters was measured using Early Treatment Diabetic Retinopathy Study (EDTRS)-like chart while participants were in a sitting position at a testing distance of 4 meters. The range of EDTRS is 0 to 100 letters. A positive change from baseline of BCVA indicates improvement. Best value on the scale 100, worst 0. The number of participants maintaining ≥10 letters gains in BCVA (compared to the baseline BCVA \[Day 0\]) value for each visit from Month 3 onwards were reported.

Time frame:
Baseline, Month 3, 6, 8 and 11
Reported as:
Count of participants · Participants
Visual Acuity: Number of Participants Keeping a BCVA Score Gain ≥10 Letters
ParticipantsRanibizumab
Month 38
Month 64
Month 83
Month 111
SecondaryVisual Acuity: Number of Participants Keeping a BCVA Score Gain ≥15 Letters

Best-Corrected Visual Acuity (BCVA) letters was measured using Early Treatment Diabetic Retinopathy Study (EDTRS)-like chart while participants were in a sitting position at a testing distance of 4 meters. The range of EDTRS is 0 to 100 letters. A positive change from baseline of BCVA indicates improvement. Best value on the scale 100, worst 0. The number of participants maintaining ≥15 letters gains in BCVA (compared to the baseline BCVA \[Day 0\]) value for each visit from Month 3 onwards were reported.

Time frame:
Baseline, Months 3, 6, 8 and 11
Reported as:
Count of participants · Participants
Visual Acuity: Number of Participants Keeping a BCVA Score Gain ≥15 Letters
ParticipantsRanibizumab
Month 34
Month 63
Month 81
Month 110
SecondaryVisual Acuity: Number of Participants With a BCVA Loss ≥15 Letters at Months 8 and 11 Compared to Month 6 in the Study Eye.

Best-Corrected Visual Acuity (BCVA) letters were measured using Early Treatment Diabetic Retinopathy Study (EDTRS)-like chart while participants were in a sitting position at a testing distance of 4 meters. The range of EDTRS is 0 to 100 letters. A positive change from baseline of BCVA indicates improvement. Best value on the scale 100, worst 0. Number of participants presenting with a ≥15 letter loss in BCVA (compared to the value observed at 6 months) and leading to a treatment change (Rescue Group) for month 8 and 11 were analyzed.

Time frame:
Months 6, 8 and 11
Reported as:
Count of participants · Participants
Visual Acuity: Number of Participants With a BCVA Loss ≥15 Letters at Months 8 and 11 Compared to Month 6 in the Study Eye.
ParticipantsRanibizumab
Month 6 to Month 80
Month 6 to Month 110
SecondaryVisual Acuity : Change of BCVA From Baseline in the Study Eye (ETDRS)

Best-Corrected Visual Acuity (BCVA) letters was measured using Early Treatment Diabetic Retinopathy Study (EDTRS)-like chart while participants were in a sitting position at a testing distance of 4 meters. The range of EDTRS is 0 to 100 letters. A positive change from baseline of BCVA indicates improvement. Best value on the scale 100, worst 0. The mean variation in BCVA was compared to the baseline BCVA value \[Day 0\] over a period of 24 months for patients in the Main Group.

Time frame:
Baseline, months 1, 2, 3, 4, 5, 6, 8 and 11
Reported as:
Mean · Letters
Visual Acuity : Change of BCVA From Baseline in the Study Eye (ETDRS)
LettersRanibizumab
Month 15.45 ± 6.444
Month 25.81 ± 7.328
Month 38.05 ± 6.704
Month 49.94 ± 5.805
Month 59.88 ± 5.290
Month 611.00 ± 8.485
Month 810.40 ± 5.413
Month 1110.00 ± NA
SecondaryCentral Retinal Thickness : Change of Log OCT From Baseline in the Study Eye

Retinal thickness is assessed by optical coherence tomography (OCT) in the study eye. The retina is the light-sensitive part of the eye. OCT is a laser-based, noninvasive, diagnostic system providing high-resolution, three-dimensional images of the retina. A negative mean change from baseline indicates an improvement and a positive mean change from baseline indicates a worsening.The absolute variations of the Central Retinal Thickness (CRT) was measured using a Spectral Domain-Optical Coherence Tomography (SD-OCT) at each visit. Values were calculated as a log OCT (=log\[CRT/200\]).

Time frame:
Baseline, months 1, 2, 3, 4, 5, 6, 8 and 11
Reported as:
Mean · log[μm/200]
Central Retinal Thickness : Change of Log OCT From Baseline in the Study Eye
log[μm/200]Ranibizumab
Month 1-0.10 ± 0.117
Month 2-0.12 ± 0.122
Month 3-0.13 ± 0.123
Month 4-0.13 ± 0.104
Month 5-0.16 ± 0.096
Month 6-0.15 ± 0.120
Month 8-0.12 ± 0.062
Month 11-0.13 ± NA
SecondaryVisual Acuity : Change of BCVA From Baseline in the Study Eye (ETDRS) - Rescue Group

Best-Corrected Visual Acuity (BCVA) letters was measured using Early Treatment Diabetic Retinopathy Study (EDTRS)-like chart while participants were in a sitting position at a testing distance of 4 meters. The range of EDTRS is 0 to 100 letters. A positive change from baseline of BCVA indicates improvement. Best value on the scale 100, worst 0. The mean variation in BCVA was compared to the baseline BCVA value \[Day 0\] over a period of 24 months for patients in the Rescue Group.

Time frame:
Baseline, Months 3, 6, 8 and 11

No measurements were reported for this outcome.

SecondaryCentral Retinal Thickness : Change of Log OCT From Baseline in the Study Eye - Rescue Group

Retinal thickness is assessed by optical coherence tomography (OCT) in the study eye. The retina is the light-sensitive part of the eye. OCT is a laser-based, noninvasive, diagnostic system providing high-resolution, three-dimensional images of the retina. A negative mean change from baseline indicates an improvement and a positive mean change from baseline indicates a worsening.The absolute variations of the Central Retinal Thickness (CRT) measured using a Spectral Domain-Optical Coherence Tomography (SD-OCT) at each visit. Values were calculated as a log OCT (=log\[CRT/200\]).

Time frame:
Baseline, Months 3, 6, 8 and 11

No measurements were reported for this outcome.

SecondaryEvaluation of the Spaced Out Follow-up on Visual Functions and Quality of Life

The global score obtained on the Visual Function Questionnaire 25 (VFQ 25) was compared from baseline to months 11 and 24 for the Main group and from baseline to months 12 and 24 for the Rescue group.

Time frame:
baseline, months 11, 12 and 24

No measurements were reported for this outcome.

Adverse events

Collected over Adverse events (AEs) were collected from the patient screening onwards. However, a safety observation period which started from first injection until 4 weeks after discontinuation - up to 11 months.. Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ranibizumab0/31 (0%)2/31 (6.5%)12/31 (38.7%)
Most frequent serious events
Most frequent serious events
EventRanibizumab
Diabetes mellitus inadequate controlMetabolism and nutrition disorders1/31
OsteonecrosisMusculoskeletal and connective tissue disorders1/31
Most frequent other events
Showing 10 of 20
Most frequent other events
EventRanibizumab
GastroenteritisInfections and infestations3/31
Coronary artery stenosisCardiac disorders1/31
Eye allergy (Both eyes)Eye disorders1/31
Halo vision (Study eye)Eye disorders1/31
Macular oedema (Contralateral eye)Eye disorders1/31
Posterior capsule opacification (Contralateral eye)Eye disorders1/31
Vitreous haemorrhage (Study eye)Eye disorders1/31
Abdominal pain upperGastrointestinal disorders1/31
ChillsGeneral disorders1/31
Oedema peripheralGeneral disorders1/31

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Ranibizumab
Mean64.7 ± 7.08
Sex: Female, Male
Sex: Female, Male(Participants)Ranibizumab
Female10
Male21
08

Study locations

10 sites
  • Novartis Investigative Site
    Bobigny cedex, Seine Saint Denis 93009, France
  • Novartis Investigative Site
    Bordeaux Cedex, F-33076, France
  • Novartis Investigative Site
    Bordeaux, 33000, France
  • Novartis Investigative Site
    Creteil, 94000, France
  • Novartis Investigative Site
    Le Kremlin Bicetre Cedex, 94275, France
  • Novartis Investigative Site
    Lyon, 69002, France
  • Novartis Investigative Site
    Nice, 06000, France
  • Novartis Investigative Site
    Paris Cedex 19, 75940, France
  • Novartis Investigative Site
    Paris, 75015, France
  • Novartis Investigative Site
    Poitiers, 86021, France
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2014 to primary completion in Apr 2015, 11 months.

Results were first posted in Oct 2020, 5 years 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 8, 2014
First posted
Jan 9, 2014
StartActual
May 19, 2014
Primary completionActual
Apr 29, 2015
CompletionActual
Apr 29, 2015
Results first posted
Oct 22, 2020
Last update
Oct 22, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 22, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02032173
Responsible party
Sponsor
First posted
Jan 9, 2014
Start date
May 19, 2014
Primary completion
Apr 29, 2015
Completion
Apr 29, 2015
Results posted
Oct 22, 2020
Last update
Oct 22, 2020

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Sep 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ranibizumab

Start the discussion